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ABSTRACT
Reduced intensity conditioning (RIC) protocols are increasingly used for allogeneic hematopoietic stem cell
transplantation (HSCT) in elderly patients. We analyzed the outcome of RIC HSCT in acute myelogenous leu-
kemia (AML) patients over the age of 40 years. Forty-three AML or high-risk myelodysplastic syndrome (MDS)
patients were treated with a fludarabine and low-dose total-body irradiation (TBI)-based pretransplantation
regimen. Donors were HLA-compatible sibling (68%) or unrelated volunteers (34%). All but 2 AML patients
were in complete remission (CR) at the time of transplantation. Seventy-six percent of patients had a poor
risk profile. Hematologic recovery was fast, and primary graft failure occurred in 1 patient. Two patients with
active disease at the time of HSCT experienced ongoing relapse. Infections were diagnosed in 9 patients
(21%), and 6 patients (14%) were treated for cytomegalovirus (CMV) reactivation. Sixty percent of patients de-
veloped acute graft-versus-host disease (aGVHD), which was grade II in 40% and grade III in 12%. The cumu-
lative incidence of chronic graft-versus-host disease (cGVHD) was 33% at 1 and at 2 years. Treatment-related
mortality (TRM) was low (9%), total nonrelapse mortality (NRM) was 19%. After a median follow-up of 571
days, 16 patients (37%) experienced relapse. Median disease-free and overall survival (DFS; OS) were 24 and
31 months, respectively. There were no differences in complications and outcome between recipients of sibling
and unrelated grafts. In conclusion, fludarabine plus low-dose TBI-based RIC HSCT is effective in AML
patients over the age of 40 years without active disease at the time of transplant and is associated with low TRM.
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The major cause of death in patients with acute
myelogenous leukemia (AML) is relapse. Intensive
postremission therapy is indicated to obtain durable
responses. However, the majority of AML patients is
older than 60 years of age, and intensive chemotherapy
alone is unlikely to cure this group [1].
For many patients allogeneic hematopoietic stem
cell transplantation (HSCT) offers the highest cura-
tive potential. Since the introduction of reduced
intensity conditioning (RIC) protocols, elderly pa-
tients and those with high risk of treatment-related
mortality (TRM) have increasingly become eligible
for allogeneic HSCT. RIC regimens rely on the
graft-versus-leukemia (GVL) effect for disease eradi-
cation. Evidence for a GVL effect in AML has beenestablished by observations that patients experiencing
graft-versus-host disease (GVHD) have an increased
progression-free survival (PFS) [2] and the capability
of donor lymphocyte infusions (DLI) to introduce
complete remissions (CR) in some AML patients
relapsing after HSCT [3].
Several RIC protocols are being used, varying from
moderately myelotoxic to truly nonmyeloablative (for
reviews see [4-7]). Some retrospective studies in
AML patients demonstrated that RIC results in less
transplant toxicity but more relapses than more inten-
sive pretransplant regimens [8,9]. Others, however, did
not find a better disease outcome after myeloablative
conditioning [10,11]. A donor versus no-donor com-
parison of RIC HSCT in AML showed increased
leukemia-free and overall survival (OS) for the181
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50 years or with significant comorbidity [12]. Another
study demonstrated superior outcome after RIC
HSCT compared to chemotherapy in patients 50 years
or older in CR1 [13].
Until now, no prospective randomized trials com-
paring myeloablative conditioning with RIC in AML
patients were available, and important issues regarding
the optimal RIC regimen, age limits of selected
patients, and timing of the RIC HSCT [14] are still
unanswered. The current analysis adds to the still lim-
ited evidence of single-arm phase 2 studies reporting
the results of RIC HSCT in a homogeneous group
of AML patients over the age of 40 years.
PATIENTS AND METHODS
Patients
This retrospective analysis describes 43 consecu-
tive patients with AML or high-risk myelodysplastic
syndrome (MDS) $40 years of age who received an
allogeneic RIC peripheral blood HSCT at our institu-
tion between February 2002 and July 2006. One
patient aged 27 was included in this group because of
a previous autologous SCT. Twenty-seven AML
patients had received induction therapy according to
HOVON 42 and 43 protocols with idarubicin or dau-
norubicin plus cytarabine, followed by at least 1 con-
solidation course consisting of high-dose cytarabine.
Different regimens were applied in 2 patients. Eleven
patients were treated because of relapse AML with
high-dose cytarabine (3000 mg/m2 twice a day for
6 days) before HSCT. ThreeMDS patients did not re-
ceive any previous therapy. All but 2 AML patients
were in CR at the time of transplantation.
Patient characteristics are shown in Table 1. Cyto-
genetics were grouped as good (inv[16], t[8;21], and
t[15;17]), poor (25, 27, 11q23, and complex karyo-
type), or intermediate (all others). High-risk leukemia
included CR.1, secondary leukemia from an anteced-
ent hematologic disorder, or poor cytogenetics. All pa-
tients were$5/6 matched with their donor at HLA -A,
-B, and -DR by serologic testing in case of a sibling
donor and $9/10 matched at HLA -A, -B, -C, -DR,
and -DQ by high-resolution typing for unrelated
donors.
Transplantation Procedure
The conditioning regimen consisted of fludarabine
30 mg/m2 for 3 days followed by 1 course of low-dose
total-body irradiation (TBI) (200 cGy), according to
the regimen developed by the Seattle group [15,16]
and a full non-T cell-depleted PBSC graft. Antithymo-
cyte globulin (ATG; ThymoglobulinTM, Genzyme)
was given to the 15 matched unrelated donor (MUD)
patients before fludarabine was infused, at a dose of
2 mg/kg/day for 4 days.Infection prevention consisted of ciprofloxacin and
fluconazole until granulocyte counts exceeded 0.5 
109/L. Furthermore, cotrimoxazole and valacyclovir
were given orally from day 11 until 12 months post-
transplantation or longer in the case of active GVHD,
in a dose of 480 mg twice a day and 500 mg twice
a day, respectively. Cytomegalovirus (CMV)-seroposi-
tive patient/donor combinations were monitored once
aweek during the first 120 days posttransplant byCMV
DNAPCR. Preemptive treatmentwith ganciclovir was
started when tests became positive.
Chimerism analysis was performed in T and
non-T cell fractions by PCR-based amplification
of short tandem repeat sequences. Peripheral
blood samples were scheduled at monthly inter-
vals post-SCT until complete chimerism was dem-
onstrated twice. DLI was administered in case of
(pending) relapse at a dose of 0.01 to 1.0  108
T cells/kg.
GVHD
Posttransplant immunosuppression consisted of
cyclosporin (4.5 mg/kg twice a day) in combination
with mycophenolate mofetil (MMF; 30 mg/kg/day).
In the absence of active GVHD, MMF was tapered
at 3 months posttransplant. In case no GVHD devel-
oped, dose reduction of cyclosporin started 2 weeks
after, MMF was stopped. GVHD was diagnosed
according to the Seattle criteria [17] and treated with
Table 1. Patient Characteristics
Characteristics
Total no. of patients 43
Male 24 (56%)
Female 19 (44%)
Age, years
Median 58
Range 27-69
Diagnosis
Acute myelogenous leukemia 36 (84%)
Myelodysplastic syndrome 7 (16%)
Cytogenetic risk group
Good 2 (5%)
Intermediate 29 (67%)
Poor 12 (28%)
Leukemic risk
Standard 14 (33%)
High 29 (67%)
Type of donor
Sibling 28 (66%)
Matched unrelated 15 (34%)
No. of HLA-mismatch
0 38 (88%)
1 5 (12%)
Previous SCT
Autologous 1 (2%)
Allogeneic 1 (2%)
For definitions, see Patients and Methods; SCT indicates stem cell
transplantation.
RIC HSCT in AML 1831 to 2 mg/kg/day prednisolone and resumption of full-
dose immunosuppression if applicable.
Statistical Methods
OS and disease-free survival (DFS) were estimated
by Kaplan-Meier analysis. OS was calculated from the
day of SCT death or last follow-up. DFS was calcu-
lated from the day of SCT until relapse, death, or
last follow-up. Patient characteristics were compared
by the c2 test or Fisher exact test for categoric variables
and the t-test for continuous variables. Univariate and
multivariate analyses of risk factors were performed by
logistic regression. The incidence of chronic GVHD
(cGVHD) and relapse were estimated by cumulative
incidence analysis considering death as competing
event. Death from relapse was considered as a compet-
ing event to calculate the cumulative probability of to-
tal nonrelapsemortality. For all tests, a 2-sided P-value
of#.05 was considered statistically significant. Calcu-
lations were performed using SPSS/PC1 15.0 (SPSS
Inc., Chicago IL).
RESULTS
Engraftment and Chimerism
Hematologic recovery was fast in nearly all pa-
tients. Two patients received HSCT while not in
remission and experienced ongoing relapse requiring
multiple transfusions with red blood cells and platelets.
Primary graft failure occurred in 1 patient (2%).
Therefore, 40 patients could be evaluated for engraft-
ment and chimerism.
In 29 patients (73%) neutrophils decreased to\0.5
 109/L and recovered at a median of 19 days (range:
8-29 days) after transplantation. Twenty-three percent
of patients developed a platelet count\20  109/L for
amedian duration of 10 days (range: 7-14 days). The in-
cidence of neutropenia was similar in recipients of sib-
ling and MUD transplants (71% versus 75%, P 5 .82)
but the duration of neutropenia was longer in the
MUD group (median 16 versus 22 days, P 5 .001).
Thrombocytopenia occurred in 14% of sibling and
42%ofMUDHSCT(P5 .06), andwas present at ame-
dian of 10 days in both groups (P 5 .73). The differ-
ences in incidence of thrombocytopenia and duration
of neutropenia between recipients of sibling and
MUD grafts are probably caused by the addition of
ATG in the MUD group. Red blood cell transfusions
were necessary in 14 of 40 patients (35%), whereas
platelet transfusions were administered to 7 patients
(18%).
Chimerism analysis could be performed in 80% of
patients at day 128 and demonstrated a median of
80% and 96% of donor cells in the T cell and non-T
cell fraction, respectively. At 13 months, these num-
bers were 86% and 88%, respectively, in 32 of 40
(83%) evaluable patients.Toxicity, GVHD, and Nonrelapse Mortality
Infections, mainly pneumonia, were diagnosed in 9
patients (21%). Six patients (14%) were treated for
CMV reactivation, whereas 1 patient developed EBV
reactivation after DLI. There was no significant differ-
ence in the incidence of CMV reactivations between
sibling andMUD recipients (13% versus 22%, respec-
tively, P 5 .60). Other complications occurred in
4 patients and are listed in Table 2.
Twenty-six patients (60%) developed aGVHD,
which was grade II in 17 patients and grade III in 5 pa-
tients (Table2).Twocasesof grade IIIGVHDdeveloped
after DLI, and all patients with grade III GVHD died.
The cumulative incidence of cGVHD was 33% at 1
and at 2 years. The incidence and severity of both
aGVHDandcGVHDwas similar inpatientswith related
and unrelated donors (P5 .84 and .74, respectively).
Four of patients died because of GVHD. No other
TRMoccurred andTRMwas therefore 9%. In 4 other
patients the cause of death was not transplantation-
related (1 patient died after a complicated operation
for Crohn’s disease, the second patient expired because
of a progressive dementia syndrome 3 years after
HSCT, 1 patient experienced a sudden death while in
CRwithoutGVHD1 year post-HSCT, and the fourth
patient also died unexpectedly while being abroad
1.5 years after HSCT). Total nonrelapse mortality
(NRM) was 19% (8 patients), with a cumulative
Table 2. Complications
Complications
aGVHD
Grade 0 15 (34%)
Grade 1 6 (14%)
Grade 2 17 (40%)
Grade 3 5 (12%)
Grade 4 0 (0%)
cGVHD
Limited disease 8 (19%)
Extensive disease 6 (14%)
No 26 (60%)
Not applicable* 3 (7%)
CMV reactivation
Yes 6 (14%)
No 37 (86%)
EBV reactivation
Yes 1 (2%)†
No 42 (98%)
Other complications
Infections
No. of patients 9 (21%)
No. of episodes 15
Bronchiolitis obliterans 1 (2%)
Pulmonary embolism 1 (2%)
BMT nephropathy 1 (2%)
Intestinal perforation eci 1 (2%)
*Patients surviving\ 100 days.
†After DLI.
184 C. Huisman et al.incidence of NRM of 9% at 1 year, 15% at 2 years and
19% at 3 years (Figure 1).
Relapse and Survival
After a median follow-up of 19 months (range 1 to
58 months) 22 patients were alive, 20 in CR, and 2 in
relapse. Median follow-up for survivors was 33 months
(range: 14-58 months). Sixteen patients (37%) experi-
enced relapse with a median DFS of 4 months (range:
1-24 months; see Table 3). The cumulative incidence
of relapse was 30% at 1 year and 37% at 2 and at 3 years
(Figure 1). In line with previous observations by our
group [18], patients who did not develop complete
donor chimerism or mixed chimerism with decreasing
recipient signals between 1 and 3 months posttrans-
plantation were at increased risk of relapse (P 5 .01).
One-year OS was 67%. Median DFS was 24
months, whereas medianOSwas 31months (Figure 2).
Fourteen DLIs were administered to 9 patients with
(pending) relapse. Two of these patients are still alive,
both 4 months after DLI.
alive after relapse
dead after relapse
non-relapse death
0 12 24 36 48
0,20
0,40
0,60
0,80
1,00
Figure 1.Cumulative incidence of relapse and non-relapse mortality
(months).
Table 3. Outcome
Outcome
Relapse
Yes 16 (37%)
No 27 (63%)
Disease-free survival, months
Median .24
Range 1-58
DLI (No.)
0 34 (79%)
1 5 (12%)
2 3 (7%)
3 1 (2%)
Death
Yes 21 (49%)
No 22 (51%)
Overall survival, months
Median 31
Range 1-58Table 4 shows the univariate analysis of factors
influencing outcome. Disease status was not included
as a risk factor because only 5% of patients were not
in CR at the time of transplantation. In univariate anal-
ysis AML risk was identified as a borderline significant
prognostic factors for DFS not for OS. Poor-risk AML
was also significantly associated with DFS in the mul-
tivariate analysis (P 5 .02).
DISCUSSION
Our analysis of 43 AML patients above the age of
40 years demonstrates that RIC HSCT might result
in long-termDFS and OS in about half of the patients.
These findings are underlined by the fact that the ma-
jority (67%) of the patients had a high leukemic risk
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Figure 2. Probability of disease-free and overall survival.
RIC HSCT in AML 185Table 4. Univariate Analysis of Prognostic Indicators of Disease-Free Survival (DFS) and Overall Survival (OS)
DFS OS
OR 95% CI P OR 95% CI P
Age
# 60 years, n 5 25 1.0 1.0
. 60 years, n 5 18 0.75 0.21-.266 0.66 2.36 0.68-8.15 0.18
Sex
Male, n 5 24 1.0 1.0
Female, n 5 19 2.2 0.62-7.70 0.22 0.90 0.27-3.00 0.86
Donor type
Sibling, n 5 28 1.0 1.0
MUD, n 5 15 2.86 0.76-10.53 0.12 2.00 0.56-7.16 0.29
AML risk
Standard, n 5 14 1.0 1.0
High, n 5 29 5.60 1.06-29.59 0.04 1.43 0.40-5.16 0.59
Timing of SCT
Upfront, n 5 32 1.0 1.0
After relapse, n 5 11 2.64 0.65-10.73 0.18 0.83 0.21-3.29 0.80
aGVHD
Grade 0-1, n 5 22 1.0 1.0
Grade 2-4, n 5 21 1.01 0.31-3.71 0.91 0.96 0.40-4.38 0.88
OR indicates odds ratio; CI , confidence interval; AML, acute myelogenous leukemia; MUD, matched unrelated donor; int, intermediate; SCT,
stem cell transplantation; aGVHD, acute graft-versus-host disease.profile. The patient group was selected on the basis of
age limits. It has been shown that AML patients over
the age of 40 years do not benefit from myeloablative
HSCT because of increased TRM [19]. Interestingly,
we did not find different outcomes for patients above
or below the age of 60 years, which suggests that
RIC HSCT is equally effective in all elderly AML pa-
tients above the age of 40 years. Furthermore, similar
outcome for recipients of sibling or MUD grafts was
demonstrated in our study.
Nearly all patients in our study were in CR before
undergoing transplantation. Active disease at the time
of RIC HSCT is associated with a high risk of relapse
and poor outcome [11,20-22]. If the burden of leuke-
mic cells is too high, the GVL effect is probably not
strong enough or develops too late to overcome resid-
ual disease. Therefore, CR at the time of HSCT is
a prerequisite for patient selection. As has been sug-
gested by others [4], for those patients who are in
CR, survival may be similar after RIC and myeloabla-
tive conditioning. However, no randomized trials are
available to confirm this.
GVHD remains the major cause of NRM. Some
studies have shown that in AML patients the incidence
of GVHD is lower after RIC than following myeloa-
blative conditioning [8,9], whereas others did not
find different results [20]. In our analysis, none of the
patients experienced grade IV aGVHD, but the inci-
dence of grade II-III GVHD (52%) might be higher
than in most previous reports (19%-42%) [2,11,21-
25]. Nevertheless, the TRM was remarkably low in
this elderly patient group (9%), and there were no dif-
ferences between sibling andMUD transplants. This is
probably related to the addition of ATG in the pre-transplantation regimen for recipients of MUD grafts
[26].
Our data on relapse and survival are rather prelim-
inary because of the relatively short follow-up and
small patient group. However, the 1-year DFS (61%)
and OS (67%) rates are encouraging. Most previous
RIC HSCT studies performed specifically in AML re-
port a 2- or 3-year DFS ranging from 27% to 60% and
an OS rate of 28% to 58% [9,11,21-25,27]. This wide
range probably reflects heterogeneous patient selec-
tion and treatment protocols. Another important find-
ing of our analysis is the comparable outcome in
recipients of sibling and unrelated transplants, as has
been observed by others [20,21,24]. Patients without
a sibling donor are therefore suitable candidates for
matched-unrelated transplants.
In conclusion, our report demonstrates that fluda-
rabine plus low-dose TBI-based RIC HSCT is effec-
tive in AML patients over the age of 40 years without
active disease at the time of transplant and is associated
with low TRM.
REFERENCES
1. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission
chemotherapy in adults with acute myeloid leukemia. N Engl J
Med. 1994;331:896-903.
2. Martino R, CaballeroMD, Simon JA, et al. Evidence for a graft-
versus-leukemia effect after allogeneic peripheral blood stem
cell transplantation with reduced-intensity conditioning in acute
myelogenous leukemia and myelodysplastic syndromes. Blood.
2002;100:2243-2245.
3. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leu-
kemia reactions in allogeneic chimeras. Blood. 2004;103:
767-776.
186 C. Huisman et al.4. Baron F, Storb R. Hematopoietic cell transplantation after
reduced-intensity conditioning for older adults with acute mye-
loid leukemia in complete remission. Curr Opin Hematol. 2007;
14:145-151.
5. Blaise D, Vey N, Faucher C, Mohty M. Current status of
reduced-intensity-conditioning allogeneic stem cell transplanta-
tion for acute myeloid leukemia. Haematologica. 2007;92:
533-541.
6. Lazarus HM, Rowe JM. Reduced-intensity conditioning for
acute myeloid leukemia: is this strategy correct. Leukemia.
2006;20:1673-1682.
7. Niederwieser D, Lange T, Cross M, Basara N, Al Ali H.
Reduced intensity conditioning (RIC) haematopoietic cell trans-
plants in elderly patients with AML. Best Pract Res Clin Haematol.
2006;19:825-838.
8. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative out-
come of reduced intensity and myeloablative conditioning regi-
men in HLA identical sibling allogeneic haematopoietic stem
cell transplantation for patients older than 50 years of age with
acute myeloblastic leukaemia: a retrospective survey from the
Acute Leukemia Working Party (ALWP) of the European
group for Blood and Marrow Transplantation (EBMT). Leuke-
mia. 2005;19:2304-2312.
9. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative
versus reduced-intensity conditioning regimens in the treatment
of acute myeloid leukemia and high-risk myelodysplastic syn-
drome: dose is relevant for long-term disease control after allo-
geneic hematopoietic stem cell transplantation. Blood. 2004;104:
865-872.
10. Scott BL, Sandmaier BM, Storer B, et al. Myeloablative vs non-
myeloablative allogeneic transplantation for patients with mye-
lodysplastic syndrome or acute myelogenous leukemia with
multilineage dysplasia: a retrospective analysis. Leukemia.
2006;20:128-135.
11. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hemato-
poietic stem-cell transplantation in AML and MDS using mye-
loablative versus reduced-intensity conditioning: the role of
dose intensity. Leukemia. 2006;20:322-328.
12. MohtyM, de LavalladeH, Ladaique P, et al. The role of reduced
intensity conditioning allogeneic stem cell transplantation in
patients with acute myeloid leukemia: a donor vs no donor com-
parison. Leukemia. 2005;19:916-920.
13. Estey E, de Lima M, Tibes R, et al. Prospective feasibility anal-
ysis of reduced-intensity conditioning (RIC) regimens for hema-
topoietic stem cell transplantation (HSCT) in elderly patients
with acute myeloid leukemia (AML) and high-risk myelodys-
plastic syndrome (MDS). Blood. 2007;109:1395-1400.
14. Finke J, Nagler A. Viewpoint: what is the role of allogeneic hae-
matopoietic cell transplantation in the era of reduced-intensity
conditioning—is there still an upper age limit? A focus on mye-
loid neoplasia. Leukemia. 2007;21:1357-1362.
15. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor
effects after allogeneic hematopoietic cell transplantation with
nonmyeloablative conditioning. J Clin Oncol. 2005;23:
1993-2003.16. Storb R, Yu C, Barnett T, et al. Stable mixed hematopoietic chi-
merism in dog leukocyte antigen-identical littermate dogs given
lymph node irradiation before and pharmacologic immunosup-
pression after marrow transplantation. Blood. 1999;94:
1131-1136.
17. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplan-
tation (second of two parts). N Engl J Med. 1975;292:895-902.
18. Huisman C, de Weger RA, de Vries L, Tilanus MG,
Verdonck LF. Chimerism analysis within 6months of allogeneic
stem cell transplantation predicts relapse in acutemyeloid leuke-
mia. Bone Marrow Transplant. 2007;39:285-291.
19. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of
a HOVON/SAKK donor versus no-donor analysis of myeloa-
blative HLA-identical sibling stem cell transplantation in first
remission acute myeloid leukemia in young and middle-aged
adults: benefits for whom? Blood. 2007;109:3658-3666.
20. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of non-
myeloablative and myeloablative allogeneic hematopoietic cell
transplantation for patients older than 50 years of age. Blood.
2005;105:1810-1814.
21. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment
for acute myelogenous leukemia by low-dose, total-body, irradi-
ation-based conditioning and hematopoietic cell transplantation
from related and unrelated donors. J Clin Oncol. 2006;24:
444-453.
22. Sayer HG, Kroger M, Beyer J, et al. Reduced intensity condi-
tioning for allogeneic hematopoietic stem cell transplantation
in patients with acute myeloid leukemia: disease status by mar-
row blasts is the strongest prognostic factor. BoneMarrow Trans-
plant. 2003;31:1089-1095.
23. Hallemeier C,GirgisM, BlumW, et al. Outcomes of adults with
acute myelogenous leukemia in remission given 550 cGy of sin-
gle-exposure total body irradiation, cyclophosphamide, and un-
related donor bone marrow transplants. Biol Blood Marrow
Transplant. 2004;10:310-319.
24. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell
transplantation using a reduced-intensity conditioning regi-
men has the capacity to produce durable remissions and
long-term disease-free survival in patients with high-risk acute
myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:
9387-9393.
25. Wong R, Giralt SA, Martin T, et al. Reduced-intensity condi-
tioning for unrelated donor hematopoietic stem cell transplanta-
tion as treatment for myeloidmalignancies in patients older than
55 years. Blood. 2003;102:3052-3059.
26. Meijer E, Cornelissen JJ, Lowenberg B, Verdonck LF. Antithy-
mocyteglobulin as prophylaxis of graft failure and graft-versus-
host disease in recipients of partially T-cell-depleted grafts
from matched unrelated donors: a dose-finding study. Exp
Hematol. 2003;31:1026-1030.
27. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity alloge-
neic hematopoietic stem cell transplantation for myelodysplastic
syndrome and acute myeloid leukemia with multilineage dyspla-
sia using fludarabine, busulphan, and alemtuzumab (FBC) con-
ditioning. Blood. 2004;104:1616-1623.
